Cord Blood Registry Withdraws Opposition to Americord’s Trademark
After nearly a year of effort we were finally able to resolve our trademark dispute with our competitor Cord Blood Registry (CBR Systems Inc). CBR alleged that our trademark registration for CordAdvantage infringed upon an existing trademark that they used. After carefully examining the details of each of our trademarks CBR withdrew their opposition to our mark allowing us to continue moving forward with the CordAdvantage product name. Currently in the late stages of development, CordAdvantage will utilize a proprietary process to maximize the volume of stem cells that can be harvested from cord blood found in the placenta immediately following the birth of a baby. See our recent press release on the topic in the Americord press room.